Ocular Therapeutix (NASDAQ:OCUL) Insider Sanjay Nayak Sells 1,858 Shares of Stock

Posted by Stanley Muller on May 29th, 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) insider Sanjay Nayak sold 1,858 shares of Ocular Therapeutix stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total transaction of $15,235.60. Following the transaction, the insider owned 328,795 shares of the company’s stock, valued at $2,696,119. The trade was a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Price Performance

OCUL stock opened at $9.15 on Friday. The firm has a 50 day moving average price of $8.79 and a 200-day moving average price of $10.23. Ocular Therapeutix, Inc. has a 52-week low of $6.23 and a 52-week high of $16.44. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -6.27 and a beta of 0.93. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81.

Institutional Investors Weigh In On Ocular Therapeutix

Several institutional investors have recently modified their holdings of the business. Hilton Head Capital Partners LLC boosted its position in shares of Ocular Therapeutix by 30.4% during the first quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,053 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its position in shares of Ocular Therapeutix by 124.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,242 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Ocular Therapeutix by 1.8% during the second quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock valued at $674,000 after buying an additional 1,314 shares during the last quarter. Trust Co. of Vermont boosted its position in shares of Ocular Therapeutix by 24.3% during the fourth quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,750 shares during the last quarter. Finally, Profund Advisors LLC boosted its position in shares of Ocular Therapeutix by 9.9% during the third quarter. Profund Advisors LLC now owns 25,178 shares of the biopharmaceutical company’s stock valued at $294,000 after buying an additional 2,272 shares during the last quarter. 59.21% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OCUL has been the subject of several recent research reports. Wall Street Zen lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Jefferies Financial Group reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Chardan Capital reiterated a “buy” rating and set a $21.00 target price on shares of Ocular Therapeutix in a report on Wednesday, February 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Tuesday, April 21st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ocular Therapeutix currently has an average rating of “Moderate Buy” and an average target price of $23.78.

View Our Latest Stock Report on OCUL

About Ocular Therapeutix

(Get Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.